$POAI
Predictive Oncology Inc. Stock $poai

$poai Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000117184324002875 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$278.7K	$419.6K
YoY Change	-43.13%	74.93%
Cost Of Revenue	$153.0K	$187.4K
YoY Change	-4.25%	56.0%
Gross Profit	$125.8K	$232.2K
YoY Change	-61.93%	93.92%
Gross Profit Margin	45.12%	55.34%
Selling, General & Admin	$2.422M	$3.367M
YoY Change	-22.72%	24.41%
% of Gross Profit	1925.67%	1449.77%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$157.3K	$162.6K
YoY Change	-9.13%	-31.65%
% of Gross Profit	125.09%	70.0%
Operating Expenses	$3.315M	$4.469M
YoY Change	4.81%	62.8%
Operating Profit	-$3.189M	-$4.237M
YoY Change	-19.45%	22.27%
Interest Expense	$360.00	$1.010K
YoY Change	-95.08%	6.32%
% of Operating Profit
Other Income/Expense, Net	$7.630K	$16.92K
YoY Change	-73.27%	-59.93%
Pretax Income	-$3.181M	-$4.219M
YoY Change	-18.92%	23.29%
Income Tax
% Of Pretax Income
Net Earnings	-$3.181M	-$4.219M
YoY Change	-18.92%	23.29%
Net Earnings / Revenue	-1141.37%	-1005.33%
Basic Earnings Per Share	-$0.68	-$1.04
Diluted Earnings Per Share	-$0.68	-$1.04
COMMON SHARES
Basic Shares Outstanding	4.102M	4.063M
Diluted Shares Outstanding	4.665M	4.063M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.332M	$5.197M
YoY Change	-63.89%	-72.05%
Cash & Equivalents	$5.332M	$5.197M
Short-Term Investments
Other Short-Term Assets	$597.7K	$412.9K
YoY Change	56.79%	-20.59%
Inventory	$568.2K	$441.7K
Prepaid Expenses
Receivables	$387.0K	$509.4K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$6.885M	$6.561M
YoY Change	-56.89%	-66.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$910.2K	$1.088M
YoY Change	-41.23%	-38.61%
Goodwill
YoY Change
Intangibles	$238.7K	$245.6K
YoY Change	-10.31%	-10.03%
Long-Term Investments
YoY Change
Other Assets	$121.1K	$124.1K
YoY Change	-30.44%	-28.72%
Total Long-Term Assets	$3.702M	$4.040M
YoY Change	-25.92%	-23.51%
TOTAL ASSETS
Total Short-Term Assets	$6.885M	$6.561M
Total Long-Term Assets	$3.702M	$4.040M
Total Assets	$10.59M	$10.60M
YoY Change	-49.51%	-57.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.563M	$1.729M
YoY Change	54.22%	21.39%
Accrued Expenses	$1.947M	$1.905M
YoY Change	17.97%	35.46%
Deferred Revenue	$269.9K	$304.3K
YoY Change	-57.01%	-52.39%
Short-Term Debt	$276.9K	$38.04K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.619M	$4.517M
YoY Change	22.72%	15.51%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.66K	$3.507K
YoY Change	-99.45%	-99.86%
Total Long-Term Liabilities	$13.66K	$3.507K
YoY Change	-99.45%	-99.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.619M	$4.517M
Total Long-Term Liabilities	$13.66K	$3.507K
Total Liabilities	$6.493M	$6.548M
YoY Change	3.69%	0.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$175.2M	-$172.0M
YoY Change	8.71%	9.4%
Common Stock	$57.09K	$40.63K
YoY Change	42.5%	2.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.094M	$4.054M
YoY Change
Total Liabilities & Shareholders Equity	$10.59M	$10.60M
YoY Change	-49.51%	-57.7%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$3.181M	-$4.219M
YoY Change	-18.92%	23.29%
Depreciation, Depletion And Amortization	$157.3K	$162.6K
YoY Change	-9.13%	-31.65%
Cash From Operating Activities	-$3.218M	-$3.416M
YoY Change	-9.97%	-0.34%
INVESTING ACTIVITIES
Capital Expenditures	$6.480K	$3.032K
YoY Change	-97.5%	-87.56%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$6.480K	-$3.032K
YoY Change	-97.5%	-93.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.359M	-$112.4K
YoY Change
NET CHANGE
Cash From Operating Activities	-3.218M	-$3.416M
Cash From Investing Activities	-6.480K	-$3.032K
Cash From Financing Activities	3.359M	-$112.4K
Net Change In Cash	134.5K	-$3.531M
YoY Change	-103.51%	1.64%
FREE CASH FLOW
Cash From Operating Activities	-$3.218M	-$3.416M
Capital Expenditures	$6.480K	$3.032K
Free Cash Flow	-$3.225M	-$3.419M
YoY Change	-15.88%	-0.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Assets Current AssetsCurrent	6561323	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	10078431	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1233910	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	245594	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	252457	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2582456	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2728355	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	124096	usd
CY2024Q1	us-gaap	Assets Assets	10601187	usd
CY2023Q4	us-gaap	Assets Assets	14417249	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1729126	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1342027	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	38036	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	150408	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1904612	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1631702	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	367	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1376	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	304320	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	308091	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	540200	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	517427	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4516661	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3951031	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4062853
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4062853
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	40629	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	40629	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175992976	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175992242	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171980726	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167761883	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4053671	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8271780	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10601187	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14417249	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	239895	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4218843	usd
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001446159
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	pure
CY2024Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2024Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	pure
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1087718	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	124096	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3507	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5459	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2027348	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2188979	usd
CY2024Q1	us-gaap	Liabilities Liabilities	6547516	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6145469	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	232231	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2627076	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2335984	usd
CY2024Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1102193	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	878518	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	739734	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	370237	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	4469003	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	3584739	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4236772	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3464983	usd
CY2024Q1	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	18657	usd
CY2023Q1	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	42228	usd
CY2024Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1737	usd
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	-0	usd
CY2024Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1009	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	953	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4218843	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3421802	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4062853
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3968099
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8271780	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	734	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4053671	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21765892	usd
CY2023Q1	poai	Stock Issued During Period Value Issued For Services And Other Adjustments StockIssuedDuringPeriodValueIssuedForServicesAndOtherAdjustments	201008	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	0	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	18554385	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4218843	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3421802	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	162565	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	237854	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	734	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9287	usd
CY2024Q1	poai	Equity Instruments Issued For Management And Consulting EquityInstrumentsIssuedForManagementAndConsulting	0	usd
CY2023Q1	poai	Equity Instruments Issued For Management And Consulting EquityInstrumentsIssuedForManagementAndConsulting	11112	usd
CY2024Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-1009	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-953	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-0	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-903	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	175748	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-48433	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-52656	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-50201	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-108775	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	91682	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	380621	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	331332	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	279951	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-639611	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3771	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	37165	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1952	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3416021	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3427761	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3032	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24369	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22274	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3032	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46643	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	112372	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-112372	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3531425	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3474404	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8728660	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22071523	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5197235	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18597119	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1737	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2922365	usd
CY2024Q1	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	0	usd
CY2023Q1	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	794	usd
CY2024Q1	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	189896	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6478	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	146205	usd
CY2024Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	usd
CY2023Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	3495	usd
CY2024Q1	poai	Number Of Tumor Samples NumberOfTumorSamples	150000	pure
CY2024Q1	poai	Number Of Tumor Samples NumberOfTumorSamples	150000	pure
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171980726	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5197235	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4516661	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2027348	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3416021	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Accounting Policies and Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, fair value of long-lived assets for impairment analyses, the valuation allowance included in the deferred income tax calculation, accrued expenses, and fair value of derivative liabilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Note 1 to the annual consolidated financial statements contained in the Annual Report on Form 10-K filed with the SEC on March 28, 2024, describes the significant accounting policies and estimates used in preparation of the consolidated financial statements. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	509445	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	333697	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	307827	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	313550	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	16974	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4821980	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3741172	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3588070	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1087718	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	278755	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	239998	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	162963	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	254376	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	441718	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	494374	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4828890	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1233910	usd
CY2024Q1	us-gaap	Depreciation Depreciation	155702	usd
CY2023Q1	us-gaap	Depreciation Depreciation	231189	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6863	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6665	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	20588	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	27451	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	27451	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	27451	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	27451	usd
CY2024Q1	poai	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	115202	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	245594	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	227641	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	214015	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M3D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M3D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	597863	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	857622	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	803724	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	827909	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	139022	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3226140	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	658592	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2567548	usd
CY2022Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	13833	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	953	usd
CY2023Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	12880	usd
CY2023Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	1376	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1009	usd
CY2024Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	367	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.908	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1806589
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	21.52
CY2024Q1	poai	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	0
CY2024Q1	poai	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	0
CY2024Q1	poai	Class Of Warrant Or Right Forfeited During Period ClassOfWarrantOrRightForfeitedDuringPeriod	-0
CY2024Q1	poai	Class Of Warrant Or Right Expired During Period ClassOfWarrantOrRightExpiredDuringPeriod	7159
CY2024Q1	poai	Class Of Warrant Or Right Expired During Period Exercise Price ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice	200
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1799430
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	20.81
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	734	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9287	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	779	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4218843	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3421802	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4062853
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3968099
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4062853
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3968099
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2024Q1	poai	Number Of Tumor Samples NumberOfTumorSamples	150000	pure
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	419646	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	162565	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4218843	usd
CY2024Q1	us-gaap	Assets Assets	10601187	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	239895	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	237854	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3421802	usd
CY2023Q4	us-gaap	Assets Assets	14417249	usd

Files In Submission

Name	View Source	Status
0001171843-24-002875-index-headers.html	Edgar Link	pending
0001171843-24-002875-index.html	Edgar Link	pending
0001171843-24-002875.txt	Edgar Link	pending
0001171843-24-002875-xbrl.zip	Edgar Link	pending
ex_668497.htm	Edgar Link	pending
ex_668498.htm	Edgar Link	pending
ex_668499.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
poai-20240331.xsd	Edgar Link	pending
poai20240331_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
poai-20240331_cal.xml	Edgar Link	unprocessable
poai-20240331_def.xml	Edgar Link	unprocessable
poai-20240331_pre.xml	Edgar Link	unprocessable
poai20240331_10q_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
poai-20240331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$POAI
Predictive Oncology Inc. Stock $poai

2024 Q2 Form 10-Q Financial Statement

#000117184324002875 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$POAI Predictive Oncology Inc. Stock $poai

2024 Q2 Form 10-Q Financial Statement

#000117184324002875 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$POAI
Predictive Oncology Inc. Stock $poai